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Increased activity of T follicular helper (Tfh) cells
plays a major pathogenic role in systemic lupus ery-
thematosus (SLE). However, the mechanisms that
cause aberrant Tfh cell responses in SLE remain
elusive. Here we showed the OX40 ligand (OX40L)-
OX40 axis contributes to the aberrant Tfh response
in SLE. OX40L was expressed by myeloid antigen-
presenting cells (APCs), but not B cells, in blood
and in inflamed tissues in adult and pediatric SLE pa-
tients. The frequency of circulating OX40L-express-
ing myeloid APCs positively correlated with disease
activity and the frequency of ICOS+ blood Tfh cells
in SLE. OX40 signals promoted naive and memory
CD4+ T cells to express multiple Tfh cell molecules
and were sufficient to induce them to become func-
tional B cell helpers. Immune complexes containing
RNA induced OX40L expression on myeloid APCs
via TLR7 activation. Our study provides a rationale
to target the OX40L-OX40 axis as a therapeutic
modality for SLE.
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic systemic in-
flammatory autoimmune disease characterized by a breakdown
of tolerance to nuclear antigens (Tsokos, 2011). A more compre-
hensive understanding of SLE pathogenesis is long overdue; in
the past 50 years, only one new drug has been approved for
SLE treatment (Murphy et al., 2013; Stohl et al., 2012).
Genome-wide association studies (GWAS) have identifiedmany susceptibility loci for SLE, confirming that SLE patients
display predisposing genetic factors (Cunninghame Graham
et al., 2008; Delgado-Vega et al., 2009). Such predisposing ge-
netic factors affect the immune system in particular when chal-
lenged with environmental factors and alter the functions of anti-
gen-presenting cells (APCs) and lymphocytes in SLE patients.
APCs including dendritic cells (DCs) are aberrantly activated in
SLE patients and promote the activation of autoreactive T and
B cells (Blanco et al., 2001; Blanco et al., 2008). The developed
autoreactive plasma cells produce pathogenic autoantibodies
directed against nuclear components and cause tissue injury.
Studies with murine models have demonstrated that T follic-
ular helper cells (Tfh), a CD4+ helper T (Th) cell subset specialized
for provision of help to B cells, play a major pathogenic role in
lupus (Crotty, 2014; Ueno et al., 2015). Tfh cells are essential
for the formation of germinal centers (GCs), the site for the selec-
tion of high-affinity B cells, and for the development of B cell
memory (Vinuesa and Cyster, 2011). Tfh cells are equipped
with multiple features required for B cell help. IL-21 secreted
by Tfh cells and their precursors (Bentebibel et al., 2011; Bryant
et al., 2007) potently promotes the growth, differentiation, and
class-switching of B cells (Tangye et al., 2013). Inducible co-
stimulator (ICOS) is highly expressed by GC Tfh cells and medi-
ates the interaction with B cells (Crotty, 2014). CD40 ligand
(CD40L) expressed by Tfh cells provides signals to B cells
through CD40 for their differentiation and class-switching
(Ueno et al., 2015). The importance of these Tfh molecules in
lupus pathogenesis is underscored by the observations in lupus
mouse models where inhibition of the function of CD40L (Boum-
pas et al., 2003; Kalled et al., 1998), ICOS (Odegard et al., 2008),
IL-21, and/or IL-21 receptor (Bubier et al., 2009; Herber et al.,
2007) delays the disease course and/or improves the clinical
symptoms. Furthermore, inhibition of the generation of Tfh
cells in lupus prone sanroquemice by deleting SAPmolecule ab-
rogates the development of renal pathology (Linterman et al.,Immunity 42, 1159–1170, June 16, 2015 ª2015 Elsevier Inc. 1159
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Figure 1. Increased OX40L Expression by Myeloid APCs in Inflammatory Tonsils
(A) Expression of OX40L, ICOSL, 4-1BBL, and GITRL on myeloid CD11c+HLA-DR+ APCs from pediatric tonsils. A representative result out of nine independent
experiments.
(B) Frequency of OX40L+, ICOSL+, GITRL+, and 4-1BBL+ cells within tonsillar myeloid APCs. Mean ± SD, n = 9. One way ANOVA. ***p < 0.001.
(C) OX40L+CD11c+ APCs in inflammatory tonsils. GC, germinal center; MZ, mantle zone; Epi, Epithelial layers. The scale bars on the top and the bottom panels
shows 100 mm and 10 mm, respectively.2009). These studies provide a strong rationale that inhibition
of the generation and/or activity of Tfh cells is beneficial for the
prevention of lupus disease from subjects with susceptible loci
and/or for the treatment of lupus patients.
In human SLE, a majority of IgG class autoantibody-producing
B cells are somatically mutated (Tiller et al., 2007), suggesting
that they are derived from GCs through interactions with Tfh
cells. The frequency of blood Tfh cells with active phenotype is
increased in active SLE patients (He et al., 2013; Simpson
et al., 2010). Furthermore, Tfh cells are also found in T cell and
B cell aggregates and ectopic germinal centers in kidneys of
patients with lupus nephritis (Chang et al., 2011; Liarski et al.,
2014). These observations support the pathogenic role of Tfh
cells in human SLE. However, the mechanisms involved in
increased Tfh response in SLE patients remains unknown.
Here we show that the OX40 ligand (OX40L)-OX40 axis con-
tributes to the aberrant Tfh cell response in SLE. OX40L was ex-
pressed by myeloid APCs, but not by B cells, in blood of adult
and pediatric active SLE patients. In inflamed tissues of SLE
patients, OX40L was expressed by various types of cells
including myeloid APCs, but not B cells. OX40L stimulation
induced human Th cells to express Tfh cell-associated mole-
cules and was sufficient to induce them to become functional
B cell helpers. Finally, we show that immune complexes (ICs)
containing ribonucleoprotein (RNP) present in lupus sera induce1160 Immunity 42, 1159–1170, June 16, 2015 ª2015 Elsevier Inc.OX40L expression by myeloid APCs through activation of
TLR7. Thus, our study shows that the RNP IC-OX40L axis likely
provides an amplification loop of the generation of autoanti-
bodies in SLE.
RESULTS
OX40L Is Abundantly Expressed in Inflamed Tonsils
We previously demonstrated that dermal CD14+ DCs preferen-
tially induce the generation of Tfh-like cells in vitro (Klechevsky
et al., 2008). CD206+ DCs in the lymph nodes, a proposed coun-
terpart of migrating dermal CD14+ DCs, also appear to share this
property (Segura et al., 2012). While these observations suggest
the involvement of dermal CD14+ DCs in the generation of Tfh
cells in draining lymph nodes of skin, the phenotype of APCs
associated with Tfh responses in inflammatory lymphoid organs
such as tonsils has not been determined.
Previous studies in mouse models demonstrated the impor-
tance of ICOS ligand (ICOSL) expressed by DCs for the differen-
tiation of Tfh cells (Choi et al., 2011). We analyzed whether
myeloid APCs (CD11c+HLA-DR+) express ICOSL in pediatric
tonsils that are enriched with mature Tfh cells along with GCs
(Bentebibel et al., 2011). Consistent with a previous report
(Aicher et al., 2000), ICOSL was not expressed at detectable
levels on either CD11c+ APCs or B cells (Figures 1A and 1B;
data not shown). Staining of tonsil tissue sections with three
different anti-ICOSL clones or with an ICOS-Ig chimera protein
also failed to detect ICOSL+ cells (data not shown). Because
low ICOSL expression might be due to chronic interactions
with ICOS+ cells at sites (Witsch et al., 2002), we examined the
expression of ICOSL transcripts by RNA-FISH in frozen human
tonsil tissues. We found that ICOSL transcript was expressed
within GCs at higher density than outside GCs (Figure S1). The
expression of ICOSL transcript was largely consistent with the
expression of CD19 transcript, suggesting that the major source
of ICOSL transcripts was B cells (Figure S1).
We found instead that CD11c+HLA-DR+ myeloid APCs, in
particular CD14+ cells, expressed the co-stimulatory molecule
OX40L (9.3% ± 7.1% of CD11c+HLA-DR+ cells, mean ± SD,
n = 9; Figure 1A). Other tumor necrosis factor (TNF) ligand family
molecules such as GITRL and 4-1BBL were undetectable or ex-
pressed only minimally (Figures 1A and 1B). OX40L expression
by myeloid APCs was nearly absent in spleen (0.3% ± 0.5% of
CD11c+HLA-DR+ cells, mean ± SD, n = 4), where Tfh and GC re-
sponses are much less evident than in pediatric tonsils (Bentebi-
bel et al., 2013). This suggests that among secondary lymphoid
organs, the presence of OX40L+myeloid APCs is limited to those
with strong inflammatory response.
To determine the localization, we stained tonsil tissues with
anti-OX40L and anti-CD11c and analyzed them by immunofluo-
rescence microscopy. We found that OX40L was abundantly
expressed in tonsils, particularly the subepithelial area, T cell
zones, and mantle zones, but less in GCs (Figure 1C). OX40L+
CD11c+ myeloid APCs were mainly found in the T cell zone (Fig-
ure 1C). The frequency of OX40L+ cells among myeloid APCs
(CD11c+) was 20.5% ± 10.4% (mean ± SD, n = 6. Range
10.7%–35.5%). RNA-FISH analysis also demonstrated the pres-
ence of cells expressing both CD14 and OX40L transcript mainly
in T cell zone (Figure S1). Consistent with the fact that OX40L can
be expressed by a broad range of immune cells including B cells,
vascular endothelial cells, mast cells, activated NK cells, and
activated Th cells (Croft, 2010), OX40L was also expressed by
CD11c cells, including B cells. The frequency of OX40L+ B cells
largely varied among tonsil tissues and among GCs in a given
tonsil tissue (20.2% ± 15.4%; mean ± SD, n = 11. Range
2.3%–51.6%). Our observation suggests that inflammatory envi-
ronment induces upregulation of OX40L expression on multiple
types of cells.
Myeloid APCs from Active SLE Patients Express OX40L
Given prominent expression of OX40L in inflamed tonsils, we
wondered whether OX40L was also expressed in inflammatory
tissues from SLE patients. We found that OX40L was abundantly
expressed by CD11c+ myeloid APCs in inflammatory kidney tis-
sues from active adult SLE patients with nephritis, but absent in
tissues from subjects without autoimmune diseases (Figure 2A).
OX40L+ myeloid APCs were also found in skin biopsy samples
from SLE patients, but not from controls (Figure 2A). ICOSL
expression was not detected by any cells (data not shown).
Similar to tonsils, OX40L+ CD11c cells were also present in
both tissues from SLE patients, but no OX40L+ B cells were
found in any tissues (Figure S2A).
We next analyzed whether peripheral myeloid APCs in pa-
tients with SLE also express OX40L. OX40L expression wassignificantly increased on the surface of blood myeloid APCs
from adult and pediatric patients with active SLE compared
to healthy subjects, inactive SLE patients, and other autoim-
mune disease patients (Figure 2B; Figure S2B). Similar to
tonsillar myeloid APCs (Figures 1A and 1B), we did not observe
the expression of ICOSL, GITRL, or 4-1BBL on blood myeloid
APCs (Figures S2C and S2D). To determine whether OX40L
expression was also increased on B cells in SLE patients, we
analyzed the expression of OX40L on blood CD11c+ APCs
and B cells side-by-side by including markers in a same stain-
ing panel. Both in adult and pediatric SLE blood samples,
OX40L expression by B cells was minimal and significantly
lower than CD11c+ APCs (percentage of OX40L+ cells in
CD11c+ APCs and B cells: 11.0% ± 2.5% versus 0.6% ±
0.3% in adult SLE (mean ± SEM, n = 19, p < 0.0001 by paired
t test), and 10.5% ± 1.3% versus 2.7% ± 0.6% in pediatric SLE
(n = 28, p < 0.0001); Figure S2E.
The percentage of OX40L+ myeloid APCs in blood was signif-
icantly higher in active patients (assessed by the SLE Disease
Activity Index [SLEDAI]) than in inactive patients, both in
adult and pediatric SLE (Figure 2C). Furthermore, the frequency
of OX40L+ cells within myeloid APCs correlated with disease
activity as assessed by the SLEDAI in both adult and pediatric
SLE (Figure 2D). OX40L was mainly expressed by CD14+
CD16+ and CD14+CD16 monocytes in blood (Figure 2E; Fig-
ure S2F). In a longitudinal follow-up of ten flaring and previously
untreated adult SLE patients, the percentage of OX40L+ myeloid
APC substantially decreased after treatment along with the
decrease in disease activity (Figure S2G, p < 0.01). Taken
together, these results show that OX40L is expressed on blood
and tissue-infiltrating myeloid APCs, but not on B cells, in active
SLE patients.
OX40 Signals Promote the Expression of Tfh Genes
in Naive and Memory T Cells
The presence of OX40L+ myeloid APCs in blood and inflamed
tissues suggests that OX40L expression is globally increased
on myeloid APCs in active SLE patients. In particular, inflamed
tissues in SLE patients appear to create an OX40L-rich environ-
ment where Th cells receive OX40 signals from multiple cell
sources (Figure 2A). While being important for proliferation
and survival, OX40 signals also regulate the differentiation
of Th cells in collaboration with other factors derived from
APCs, microenvironment, and Th cells themselves (Croft,
2010). We hypothesized that OX40 signals might display an
intrinsic property to promote the differentiation of human Th
cells toward the Tfh lineage. To address this hypothesis, we
applied an APC-free system to avoid the contribution of factors
from APCs and microenvironment and cultured naive and
memory Th cells with anti-CD3 and anti-CD28 in the presence
of agonistic soluble OX40L (sOX40L). To minimize the influence
of T cell-intrinsic factors, we analyzed the gene-expression
profiles at 48 hr of culture by NanoString. We found that
OX40 signaling upregulated multiple Tfh genes, including
CXCR5, BCL6, IL21, CXCL13, and PDCD1 (encoding PD-1) in
both naive and memory Th cells (Figure 3A). Furthermore,
OX40L stimulation downregulated the expression of PRDM1
(encoding Blimp-1), the transcription repressor that inhibits
Tfh generation (Crotty, 2014).Immunity 42, 1159–1170, June 16, 2015 ª2015 Elsevier Inc. 1161
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Figure 2. OX40L Expression by Myeloid APCs from SLE Patients
(A) OX40L+ myeloid APCs in skin and kidney biopsies from adult SLE patients and subjects without autoimmune diseases. A representative result of five skin
and three kidney biopsy samples from SLE patients and five skin and two kidney biopsy samples from controls. Scale bar represents 100 mm.
(B) Representative flow data on OX40L expression by blood myeloid CD11c+HLA-DR+ APCs from the three groups: healthy donors (HD), inactive (iSLE),
and active (aSLE) SLE patients.
(C) Frequency of OX40L+ cells within blood myeloid APCs in the three groups in adult and pediatric cohorts. Top shows the adult cohort; 16 HD, 38 iSLE,
and 31 aSLE samples. Bottom shows the children cohort; 14 HD, 20 iSLE, and 14 aSLE samples. One-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001.
(D) Correlation between the percentage of OX40L+ cells within CD11c+HLA-DR+ myeloid APCs (adults: n = 69 and children: n = 38) and disease activity assessed
by the SLEDAI. Statistical analysis was performed with the Spearman test.
(E) Composition of blood OX40L+ myeloid APCs by different subsets (CD14+CD16, CD14+CD16+, CD14CD16, CD14CD16+) in adult (n = 28) and pediatric
(n = 34) SLE patients. Mean ± SD.Previously, we and others show that IL-12 induces activated
human naive Th cells to express multiple Tfh molecules
including IL-21, ICOS, CXCR5, and Bcl-6 at higher levels than
other cytokines (Schmitt et al., 2013; Schmitt et al., 2014;
Schmitt et al., 2009). Subjects deficient of IL-12 receptor b1
(IL-12Rb1) chain display reduced Tfh and GC responses (in
particular children), providing in vivo evidence that signals via
IL-12 receptor is essential for the generation of Tfh cell differen-
tiation in humans (Schmitt et al., 2013). Thus, we compared the
expression of Tfh genes between OX40- and IL-12-stimulated
Th cells. To our surprise, OX40 signals induced naive Th cells
to express multiple Tfh genes at equivalent levels with IL-12
signals (Figure S3). Furthermore, overall expression patterns
of Tfh genes were similar between OX40- and IL-12-stimulated1162 Immunity 42, 1159–1170, June 16, 2015 ª2015 Elsevier Inc.naive Th cells (Figure 3B, left). While mouse studies suggest
the positive role of IFN-g for the generation of Tfh cells (Lee
et al., 2012), the upregulation of Tfh molecules in these cells
was not due to IFN-g secreted in the cultures, as IFN-g-stimu-
lated naive Th cells did not show the similar gene patterns
(Figure 3B, left). The combination of the two signals further
increased the expression of IL21, but not other Tfh molecules
(Figure S3).
Importantly, in contrast to the observation with naive Th cells,
OX40 signals were more potent than IL-12 signals at inducing
memory Th cells to upregulate Tfh genes (BCL6, CXCR5,
IL-21, CXCL13, and PDCD1) and to downregulate PRDM1 (Fig-
ures 3B and 3C). It was notable that OX40 signals differentially
modulated the expression of MAF and BATF, genes associated
A B
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Figure 3. OX40 Signals Induce Upregulation
of Tfh Genes
(A) Tfh gene expression by naive and memory Th
cells (from three donors) activated with anti-CD3 and
anti-CD28 in the presence or absence of sOX40L for
48 hr. Transcript counts in the cultured Th cells are
shown after normalization to housekeeping genes.
Mean ± SD, n = 3. Paired t test. *p < 0.05, **p < 0.01.
(B) Tfh gene expression profiles by naive and mem-
ory Th cells activated with anti-CD3 and anti-CD28
in the presence of indicated reagents for 48 hr.
Transcript counts in Th cells cultured in the presence
of the indicated reagents were normalized to those
in control Th cells in each donor.
(C) Transcript counts in memory Th cells activated
with anti-CD3 and anti-CD28 in the presence of
indicated reagents. Mean ± SD, n = 3. One-way
ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001.with Tfh development and functions (Crotty, 2014), between
naive and memory Th cells. OX40 signals induced upregulation
of the two genes in naive Th cells, but downregulation in memory
Th cells (Figure 3B). Nonetheless, IL-12 signals cooperated with
OX40 signals to increase the expression of CXCR5 and IL21 by
memory Th cells (Figure 3C).
OX40 Signals Promote the Generation
of Functional Helpers
To analyze the expression of Tfh molecules at protein levels, we
activated naive and memory Th cells by anti-CD3 and anti-CD28
in the presence or absence of sOX40L for 3 days, and the pheno-
type was analyzed by flow cytometry. Consistent with transcrip-
tional data (Figures 3A and 3B), OX40 signals promoted both
naive and memory Th cells to express Tfh molecules including
CXCR5, CD40L, and IL-21, and increased the generation of
CXCR5+ cells co-expressing IL-21, CD40L, ICOS, and Bcl-6
(Figures 4A and 4B; Figure S4A). Of note, in addition to IL-21,
OX40 signals induced the expression of IL-2 and TNF-a, but
not IFN-g or IL-4 (Figure S4B) despite increased T-bet expres-
sion (Figures 4A and 4B). OX40 signals also weakly increased
the expression of RORgt, but did not induce IL-17A expression
(Figure S4C). OX40L stimulation also induced naive Th cells to
downregulate the expression of CCR7 on CXCR5+ cells (Fig-Immunity 42, 1159–1ure S4A), and increased the generation of
CXCR5+CCR7 cells, a chemokine recep-
tor expression profile required for homing
to B cell follicles (Haynes et al., 2007).
This was not due to an enhanced expres-
sion of achaete-scute homolog 2 (Ascl2),
the transcription factor important for initia-
tion of the murine Tfh cell development
(Liu et al., 2014), because Ascl2 transcript
expression was completely absent in any
culture conditions (data not shown).
Strikingly, OX40 signals inducedmemory
Th cells to express Tfh molecules including
CXCR5, CD40L, and IL-21 more efficiently
than IL-12 signals (Figure 4B). We noticed
that OX40 signals decreased the expres-sion of ICOS onmemory Th cells compared to the control culture
(Figure S4A), which was consistent with the transcriptional data
(Figure 3B). However, ICOS expression levels remained high,
and more than 80% of CXCR5+ cells stimulated with OX40 sig-
nals expressed ICOS.
We wondered whether OX40 signals are sufficient to induce
Th cells to become functional helpers. To this end, stimulated
Th cells were co-cultured with autologous B cells and the
produced IgG were measured at day 14. OX40 signals were suf-
ficient to induce both naive and memory Th cells to become
B cell helpers (Figure 4C). Notably, OX40 signals were more effi-
cient than IL-12 signals to induce memory Th cells to become
helpers (Figure 4C). These results show that OX40L stimulation
promotes naive and memory Th cells to differentiate into Tfh-
like cells.
Collectively, these results show that OX40 signals display an
intrinsic property to induce human naive and memory Th cells
to express multiple Tfh molecules and to become functional
B cell helpers.
OX40 Signals Promote the Expression of Tfh Molecules
by Enhancing TCR Signals
OX40 signals activate canonical and non-canonical NF-kB
pathways (Croft, 2010). To determine the mechanism by which170, June 16, 2015 ª2015 Elsevier Inc. 1163
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Figure 4. OX40L Stimulation Promotes the Differentiation of Naive and Memory T Cells into Tfh-like Cells
(A) Expression of CXCR5, IL-21, CD40L, Bcl-6, and T-bet by naive and memory Th cells activated with anti-CD3 and anti-CD28 in the presence or absence of
sOX40L and/or IL-12. Gated to FSChiSSChi activated cells. A representative result out of three independent experiments is shown.
(B) Frequency of CXCR5+IL-21+,CXCR5+CD40L+, CXCR5+Bcl-6+, and CXCR5+T-bet+ cells developed in naive or memory Th cells after activation with anti-CD3
and anti-CD28 in the presence or absence of sOX40L and/or IL-12. One-way ANOVA. *p < 0.05, **p < 0.01, ***p < 0.001, n = 3.
(C) Naive or memory Th cells were activated for 4 days with anti-CD3 and anti-CD28 in the presence of sOX40L and/or IL-12, and then cultured
with autologous memory B cells. IgG concentrations in the supernatant of each well are shown. A representative result out of two independent experiments
is shown.OX40 signals promote the expression of Tfh molecules, we first
analyzed whether inhibition of either canonical or non-canonical
NF-kB pathway affects the expression of Tfh molecules by
OX40-stimulated human naive Th cells. We inhibited the expres-
sion of NF-kB signaling molecules by transfecting specific
siRNA, including NF-kB1, RelA (included in canonical pathway),
NF-kB2, and RelB (involved in non-canonical pathway). Because
a previous mouse study demonstrated that TRAF6 was essential
for OX40 signals to promote the generation of Th9 cells (Xiao
et al., 2012), we also tested the role of TRAF6. We confirmed
that siRNA transfection substantially inhibited the expression of
the target protein (Figure S5A). Naive Th cells that transfected
siRNA were stimulated with CD3-CD28 mAbs in the presence1164 Immunity 42, 1159–1170, June 16, 2015 ª2015 Elsevier Inc.or absence of sOX40L, and the expression of Tfh molecules
was analyzed by flow cytometry.
Blocking molecules of canonical (NF-kB1, RelA) and non-
canonical (NF-kB2) pathways weakly but significantly inhibited
the Bcl-6 expression by OX40-stimulated CD4+ T cells (Fig-
ure 5A). However, this did not appear to depend on OX40
signals, because a similar trend was observed with the Th cells
cultured in the control condition (no sOX40L). Similarly, while
inhibition of NF-kB2 upregulated the expression of CXCR5
and IL-21 and downregulated the expression of CD40L and
ICOS, this was independent of OX40 signals (Figure S5B).
These results suggest that while NF-kB pathway can regulate
the expression of Tfh molecules, this might not be the dominant
A B Figure 5. Strong TCR stimulation induce
naive Th cells to express Tfh molecules.
(A) Bcl-6 expression by naive Th cells transfected
with the indicated siRNA and cultured for 3 days
with anti-CD3 and CD28 ± sOX40L. Gated to
FSChiSSChi activated cells. Mean ± SEM, n = 3.
(B) Expression of the indicated markers by naive
Th cells activated for 4 days with the indicated
number of anti-CD3 and anti-CD28-coated beads.
Gated to FSChiSSChi activated cells. A represen-
tative result out of three independent experiments
is shown.one by which OX40 signals induce naive Th cells to upregulate
Tfh molecules.
Recent studies demonstrate that the strength and the duration
of signals through T cell receptor (TCR) play amajor role in deter-
mining the fate of primed Th cells (Tubo et al., 2013; van Panhuys
et al., 2014). In this regard, strong and durable TCR signals pro-
mote Th differentiation toward the Tfh lineage and their prolifer-
ation (Deenick et al., 2010; Fazilleau et al., 2009; Tubo et al.,
2013). It is known that OX40 signals augment TCR signals via
the PI3K-Akt pathway (So et al., 2011). Furthermore, a recent
study shows that blood memory Th cells in pediatric SLE
patients constitutively express higher levels of phosphorylated
Akt, and OX40 signals further enhance Akt activation of these
cells (Kshirsagar et al., 2013). Therefore, it is possible that
OX40 signals promote the expression of Tfh molecules by
enhancing TCR signals. However, whether strong TCR signals
promote human Th cells to express Tfhmolecules or not remains
unknown. Therefore, we stimulated naive Th cells with titrated
numbers of anti-CD3 and anti-CD28-coated beads and analyzed
the expression of Tfh molecules. We found that the stimulation
with anti-CD3-CD28 beads promoted the expression of multiple
Tfh molecules including CXCR5, IL-21, CD40L, and Bcl-6 in a
dose-dependent manner (Figure 5B). Stronger TCR signals
also increased OX40 expression. In contrast, the expression of
IFN-g, IL-4, and IL-17A was not modified by the number of
anti-CD3-CD28 beads (Figure S5C). Thus, strong TCR signals
promote human naive Th cells to expressmultiple Tfhmolecules,
but not other Th molecules.
Collectively, these results suggest that OX40 signals promote
the expression of Tfh molecules by enhancing TCR signals.
The Frequency of OX40L+ APCs Correlates with That
of ICOS+CXCR5+ Tfh Cells in Blood
Previous studies showed that active SLE patients display an
increased frequency of blood Tfh cells with active phenotype
(ICOS+CXCR5+) (He et al., 2013; Simpson et al., 2010). We
were able to confirm this observation in our cohort (Figure 6A).
Importantly, we found that the frequency of ICOS+ cells within
blood Tfh cells positively correlated with the frequency of
OX40L+ cells within blood myeloid APCs (Figure 6B). The
frequency of OX40L+ APCs also positively correlated with
the frequency of blood Tfh cells (CXCR5+ in total Th cells)Immunity 42, 1159–117(Figure S6A), but showed no correlation
with the frequency of blood CXCR5 Th1
(CXCR3+CCR6), Th2 (CXCR3CCR6)Th17 (CXCR3CCR6+) cells (Morita et al., 2011) (Figure S6B).
These results suggest that OX40L-expressing myeloid APCs
from SLE patients promote the development and/or the activa-
tion of Tfh cells.
RNP-Anti-RNP ICs Promote OX40L Expression through
TLR7 Activation
We wondered which mechanism is involved in OX40L expres-
sion by myeloid APCs in active SLE patients. We previously
demonstrated that SLE sera induce monocytes to acquire the
properties of DCs (Blanco et al., 2001). Therefore, we hypothe-
sized that SLE sera might contain components that induce
OX40L expression by myeloid APCs. Accordingly, we found
that SLE sera, but not control sera, induced OX40L expression
on healthy donor monocytes at variable levels (Figure 7A).
Upon co-culture with allogeneic naive Th cells, monocytes
exposed to SLE sera promoted the expression of IL-21 in a
manner partly dependent on OX40L (Figures S7A and S7B).
We suspected the involvement of immune complexes (ICs) con-
taining self-nucleic acid, because activation of APCs through
endosomal nucleic acid sensors play a key role in SLE patho-
genesis (Barrat and Coffman, 2008). Indeed, stimulation with
agonist of TLR7, but not TLR9 and TLR3, induced healthy donor
monocytes to express OX40L (Figure 7B). Of note, B cells did not
express OX40L in response to stimulation with any of these TLR
ligands (Figure S7C; data not shown). While previous mouse
and human studies show that CD40 signal induces DCs to upre-
gulate OX40L expression (Fillatreau and Gray, 2003; Murata
et al., 2000; Ohshima et al., 1997), CD40 signal by itself was
insufficient to induce monocytes to express OX40L (Figure S7D).
To test whether TLR7 was directly implicated in OX40L upregu-
lation by SLE sera, we exposed monocytes to SLE sera in the
presence of a specific TLR7 inhibitor IRS-661 (Barrat et al.,
2005) or RNase. Both TLR7 inhibitor and RNase significantly
reduced the ability of SLE sera to induce OX40L expression (Fig-
ure 7C; Figure S7E), suggesting the major role by ICs containing
RNA. In agreement with this hypothesis, we observed that the
presence of anti-ribonucleoprotein (RNP), but not anti-DNA,
antibodies in SLE sera was associated with the increased ability
to promote OX40L expression on monocytes (Figure 7D).
To validate whether RNP-anti-RNP ICs were directly involved
in OX40L expression, we cultured healthy donor monocytes with0, June 16, 2015 ª2015 Elsevier Inc. 1165
A B Figure 6. The Frequency of OX40L+ Myeloid
APCs Correlates with the Frequency of
ICOS+ Blood Tfh Cells in Human SLE
(A) Expression of ICOS on blood Tfh cells in the
three groups; aSLE, iSLE, and HD. A representative
flow result is shown.
(B) Correlation between the frequency of OX40L+
cells within blood myeloid APCs and the frequency
of ICOS+ cells within blood Tfh cells in SLE patients.
Spearman correlation test, n = 19.anti-RNP negative SLE sera and spiked purified IgG-containing
RNP-anti-RNP ICs into the cultures. We found that the supple-
mentation with RNP-anti-RNP ICs rendered anti-RNP negative
SLE sera able to promote OX40L expression (Figure 7E). This ef-
fect was dependent on TLR7 because addition of TLR7-specific
inhibitor abrogated the upregulation of OX40L (Figure 7E).
These data show that RNP-anti-RNP ICs promote OX40L
expression through TLR7 activation in myeloid APCs in
active SLE.
DISCUSSION
Autoreactive antibody production is a hallmark of a variety of
autoimmune diseases including SLE. Our study provides evi-
dence that the OX40L-OX40 axis contributes to lupus pathogen-
esis by promoting the generation of Tfh cells.
The expression of OX40L by myeloid APCs, but not B cells,
was increased in blood in active SLE patients. OX40L+ myeloid
APCs in blood of active SLE patients were largely confined
to CD14+CD16 and CD14+CD16+ monocyte populations.
OX40L+ myeloid APCs in pediatric tonsils were also largely
limited to the CD14+ population. Increased OX40L expression
on blood monocyte populations was also reported in patients
with sepsis (Karulf et al., 2010) and patients with chronic hepatitis
C (Zhang et al., 2013). Interestingly, both disease conditions are
known to be often associated with hyper gammaglobulinemia.
These observations suggest that monocytes and macrophages
upregulate OX40L in inflammatory environment and contribute
to antibody responses in humans. Furthermore, various types
of cells upregulate OX40L expression in tonsils and inflammatory
tissues of SLE patients, and therefore might also provide OX40
signals to T cells.
The pathogenic roles of ICs containing self-nucleic acid are
well established in SLE. The ICs activate plasmacytoid DCs via
TLR9 and TLR7 and induce them to produce large amounts of
type I interferons (Lo¨vgren et al., 2006). Type I IFN induces neu-
trophils to upregulate TLR7 and renders them able to respond to
RNP-anti-RNP ICs. Then neutrophils produce DNA-containing
components that activate pDCs (Garcia-Romo et al., 2011;
Lande et al., 2011). RNP-anti-RNP ICs also target the CD16+
CD14dimmonocyte population and induce these cells to produce
cytokines that damage the endothelium, including TNF-a, IL-1,
and CCL3 (Cros et al., 2010). While these mechanisms involve
the activation of the innate immune system and consequent
inflammation, our study shows that RNP-anti-RNP ICs also
activate the adaptive immune system. We found that RNP-1166 Immunity 42, 1159–1170, June 16, 2015 ª2015 Elsevier Inc.anti-RNP ICs contribute to OX40L expression by monocytes
and macrophages via TLR7. Tfh responses increased by the
RNP-anti-RNP IC-OX40L axis further accelerate the generation
of autoantibodies including those against self-nucleic acid.
Therefore, the RNP-anti-RNP IC-OX40L axis appears to provide
an amplification loop of the generation of autoantibodies in SLE.
We showed that OX40 signals together with TCR and CD28
signals promote naive and memory Th cells to express multiple
Tfh molecules, including CXCR5, IL-21, and Bcl-6. Remarkably,
OX40 signals were more potent than IL-12 signals to induce
memory Th cells to express Tfh molecules and were sufficient
to render them to become efficient B cell helpers. These results
show that OX40 signals display intrinsic property to promote Th
differentiation toward the Tfh lineage in humans. Our study
further suggests that this property is mainly mediated by an
enhancement of TCR signals rather than that of the NF-kB
pathway. In this line, strong TCR signals induced human naive
Th cells to express multiple Tfh molecules including CXCR5,
IL-21, CD40L, and Bcl-6, but not other Th molecules. Thus, the
OX40L-OX40 axis contributes to Tfh development in a manner
independent of cytokine signals that activate STAT3 and
STAT4 (Schmitt et al., 2014). These twomechanisms likely coop-
erate, because human Th cells stimulated with both OX40 sig-
nals and IL-12 signals further upregulated IL-21 expression.
While previous mouse studies demonstrated a fundamental
role of ICOSL-expressing DCs for the development of Tfh cells
(Choi et al., 2011), to our surprise, we were not able to detect
myeloid APCs or B cells highly expressing ICOSL in inflamed
tonsils or SLE samples. Nonetheless, considering that ICOS
deficiency in humans results in absence of mature Tfh cells
andGCs (Bossaller et al., 2006), we do not argue the contribution
of ICOSL+ APCs for Tfh cell development in humans or for lupus
pathogenesis. Rather, our study highlights the additional contri-
bution of OX40L+ DCs to the development of Tfh response in
humans. Whether, when, and how OX40 signals and ICOS sig-
nals contribute to the development and/or maintenance of
aberrant Tfh response in human autoimmune diseases remain
to be addressed. Nonetheless, given that both OX40 signals
and ICOS signals enhance the PI3K-Akt pathway, which plays
an important role for the expression of IL-21 (Gigoux et al.,
2009), these two pathways might cooperate and/or be comple-
mentary to each other for the development of Tfh cells. Impor-
tantly, in contrast to ICOS deficiency, a recent report shows
that human OX40 deficiency seems to have intact Tfh and
antibody responses (Byun et al., 2013). This suggests that
OX40 signals are not essential for Tfh cell development or
A B C
D E
Figure 7. RNP-anti-RNP ICs Promote OX40L Expression by Myeloid APCs in a TLR7-Dependent Manner
(A) Expression of OX40L (MFI) by purified healthy donor monocytes exposed to control sera (n = 7) or SLE sera (n = 21). Mann-Whitney U-test. **p < 0.01.
A representative staining is shown on the left panel.
(B) OX40L expression upon stimulation of purified healthy donor monocytes by TLR3, TLR7, or TLR9 agonists. A representative staining out of four different
experiments is shown.
(C) Fold change in OX40L expression (MFI) in healthy donor monocytes exposed to SLE sera (n = 7) in the presence or not of a TLR7 inhibitor. Paired t test.
****p < 0.0001. A representative staining is shown on the left panel.
(D) OX40L expression (MFI) in healthy donor monocytes exposed to anti-RNPneg SLE sera (n = 5) or anti-RNPpos SLE sera (n = 16). Mann-Whitney U-test.
**p < 0.01. Mean ± SEM.
(E) OX40L expression of purified healthy donormonocytes exposed to anti-RNPneg SLE serum, the serum supplementedwith anti-RNP-containing IgG, the serum
spiked with anti-RNP-containing IgG in the presence of a TLR7 inhibitor. A representative staining out of three independent experiments is shown.sufficient to compensate ICOS deficiency in vivo in humans.
Thus, we surmise that OX40 signals cause aberrant Tfh response
and autoimmunity in humans only when excessive. The positive
correlation between the frequency of ICOS+ blood Tfh cells and
the frequency of OX40L+ myeloid APCs in active SLE patients
supports this hypothesis.
Mousemodels so far providedmixed results regarding the role
of the OX40-OX40L axis on the regulation of Tfh cell responses.
Early studies showed that OX40L stimulation promotes mouse
naive Th cells to express CXCR5 (Flynn et al., 1998), and their
migration into B cell follicles (Brocker et al., 1999; Fillatreau
and Gray, 2003). Furthermore, an OX40L-transgenic mice model
(T cell-specific overexpression) showed development an auto-
immune-like disease characterized by interstitial pneumonia,
colitis, and high levels of anti-nuclear antibodies (Murata et al.,
2002). Recent studies show that the mutation of Roquin gene
in sanroque mice causes upregulation of OX40 on Th cells, sug-
gesting the positive role of OX40 signals for the generation of Tfh
cells (Pratama et al., 2013; Vogel et al., 2013). On the other hand,
at least two studies concluded that the absence of OX40 signals
did not affect CXCR5 expression by Th cells, Tfh differentiation,
GC development, or antibody generation (Akiba et al., 2005;
Kopf et al., 1999). Furthermore, in vivo treatment with agonistic
OX40 mAb inhibited Tfh cell generation in mice in an acute viral
infection model (Boettler et al., 2013) and in a listeria infection
model (Marriott et al., 2014). Boettler et al. showed that agonisticanti-OX40 mAb enhanced the expression of Blimp-1 by specific
Th cells while suppressing the expression of Bcl-6 in vivo (Boet-
tler et al., 2013), contrary to our observations with human Th cells
in vitro. Given that OX40 signals regulate Th differentiation in
collaboration with other factors derived from APCs, microenvi-
ronment, and Th cells themselves (Croft, 2010), it is possible
that OX40 signals promote or suppress Tfh cell differentiation ac-
cording to the microenvironment where Th cells interact with
APCs. For example, in an acute viral infection model, it is
possible that OX40 signals enhanced Blimp-1 expression due
to the co-presence of Type I interferons, which strongly promote
Blimp-1 expression (Schmitt et al., 2014). It is yet possible that
OX40 signals differentially modulate the expression of Tfh mole-
cules between human and mouse Th cells.
Our conclusion is also supported by the findings in GWAS in
autoimmune diseases. TNFSF4 (encoding OX40L) polymor-
phism has been found to confer susceptibility to SLE (Cunning-
hame Graham et al., 2008; Delgado-Vega et al., 2009) and other
autoimmune diseases, such as Sjo¨gren syndrome, and rheuma-
toid arthritis (Kim et al., 2015; Nordmark et al., 2011). Further-
more, copy number variations and/or polymorphism at the
TLR7 locus has been shown to associate with SLE susceptibility
(Shen et al., 2010). Our study provides a rationale that therapeu-
ticmodalities targeting the RNP-containing IC-OX40L-OX40 axis
and TLR7 could impact the development of autoantibodies and
therefore be beneficial for human SLE.Immunity 42, 1159–1170, June 16, 2015 ª2015 Elsevier Inc. 1167
EXPERIMENTAL PROCEDURES
Patient Samples
For adult SLE samples, blood samples from routine lab analysis were used
after informed consent was obtained. For pediatric SLE samples, the study
was approved by the Institutional Review Board of Baylor Research Institute
and informed consent was obtained from all the participants or their legal
guardian. Adult SLE patients (total 61: 53 female and 8 male) and pediatric
SLE patients (total 38: 34 female and 4 male) who met the American College
of Rheumatology revised criteria for SLE were enrolled. All clinical and biolog-
ically relevant information of the patients is shown in Tables S1 and S2. Clinical
disease activity was assessed using the SLE Disease Activity Index (SLEDAI).
Active patients were defined as SLEDAI scoreR 6.
Phenotyping of Blood Immune Cells by Flow Cytometry
For the analysis of OX40L expression, whole blood samples were stained with
anti-CD14-PC5, CD16-FITC, CD11c-APC, HLA-DR-PC7, and OX40L-PE
mAbs, and red blood cells were lysed with Versalyse (Beckman Coulter).
For the analysis of blood Tfh cells, whole blood samples were stained with
anti-CXCR5-AF488, CCR6-PE, CXCR3- PC5, CCR4-PC7, CD3-AF700, CD8-
APCH7, CD4-Pacific Blue (all from Becton Dickinson), CD45RA-ECD (Beck-
man Coulter), ICOS-APC (Biolegend), and CD45-Pacific Orange (Invitrogen).
Data were collected using a BD LSR II instrument (BD Biosciences) and
analyzed with Flowjo software (Tree Star).
Culture of Th Cells
Naive (CD45RA+CCR7+) and memory (CD45RA) Th cells were sorted by flow
cytometry as described before (Schmitt et al., 2009). Th cells were stimulated
overnight with CD3/CD28 Dynabeads (Invitrogen) in RPMI complete medium
supplemented with 10% FCS. In some experiments, overnight stimulated
naive Th cells were transfected with either control or TRAF6 (s14389),
NFkB1 (s9504), NFkB2 (s9507), RelA (s11916), or RelB (s11919)-specific
siRNA (Life Technologies) as previously described (Schmitt et al., 2009). Cells
were then transferred to flat-bottomed 96 well plates coated with CD3 mAb
(5 mg /ml, OKT3) supplemented with soluble CD28 mAb (1 mg/ml, CD28.2), in
the presence or absence of recombinant IL-12 (100 pg/ml), and/or soluble
OX40L (100 ng/ml, R&D systems). T cells were harvested at day 4 (for CD3/
CD28 stimulated T cells) or at day 7 (for monocyte-T co-culture) for phenotyp-
ing with anti-CXCR5 AF647, anti-CD40L APC-eFluor 780, and anti-ICOS
biotin/Streptavidin-PerCP; and for co-culture with B cells. For the assessment
of IL-21 expression (with anti-IL21-PE), cultured cells were re-stimulated with
25 ng/ml PMA, 1 mg/ml ionomycin for 6 hr in the presence of brefeldine and
monensin for the last 4 hr.
Co-Culture of Th and B Cells
Activated Th cells were co-cultured with autologous memory B cells (5 3 103
T cells for 40 3 103 memory B cells per well) in 96-well round-bottom plates
in Yssel medium/10% FBS in the presence of endotoxin-reduced SEB
(0.25 ng/ml; Toxin Technology). IgG produced in the cultures were analyzed
by ELISA at day 14.
Culture of Monocytes
CD14+ monocytes were purified from blood samples from healthy donors by
negative selection (Stemcell) and then exposed to SLE serum (10%) or control
serum for 3 days in a 6 well-plate. The phenotype was analyzed by FACS
with anti-CD14-PC5, anti-HLA-DR-PC7, and anti-OX40L-PE. TLR3 (poly-IC,
10 mg/ml), TLR7 (R837, 5 mg/ml), TLR9 (ODN2216, 10 mg/ml) agonists were
purchased from InvivoGen. The TLR7 inhibitor IRS-661 (1 mM) (Barrat et al.,
2005) was incubated for 10 min with the monocytes before the addition of
SLE serum or anti-RNP IgG (50 mg/ml).
Statistical Analysis
When the normality of the distribution was rejected, non-parametric paired
Wilcoxon test or unpaired Mann-Whitney U tests were used. One-way
ANOVA with multiple comparison tests was used to compare more than
three parameters. Correlation between variables was determined by using
the Spearman test.
Additional Supplemental Experimental Procedures are available online.1168 Immunity 42, 1159–1170, June 16, 2015 ª2015 Elsevier Inc.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures, two tables, and Supple-
mental Experimental Procedures and can be found with this article online
at http://dx.doi.org/10.1016/j.immuni.2015.05.012.AUTHOR CONTRIBUTIONS
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